Qualifying for semaglutide depends on which condition you’re treating and which version of the drug you’re seeking. For weight management, the core threshold is a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition. For type 2 diabetes, the qualification is a confirmed diagnosis with no specific lab value required. Beyond the medical criteria, insurance coverage adds its own layer of requirements that can be harder to clear than the prescription itself.
Two Drugs, Different Qualifications
Semaglutide is sold under two main brand names, and the qualifying criteria differ for each. Ozempic is approved for adults with type 2 diabetes to improve blood sugar control and reduce the risk of heart attack, stroke, and cardiovascular death in those with established heart disease. Wegovy is the version approved for chronic weight management, with a broader and more recently expanded set of indications.
Your doctor prescribes one or the other based on your primary condition. You won’t qualify for Ozempic without a type 2 diabetes diagnosis, and Wegovy’s weight management indication requires meeting specific BMI thresholds. Using one brand “off-label” for the other condition is technically possible but creates problems with insurance coverage and dosing.
BMI Thresholds for Weight Management
To qualify for Wegovy for weight loss, you need to meet one of two BMI criteria:
- BMI of 30 or higher (classified as obesity), with no additional conditions required.
- BMI of 27 to 29.9 (classified as overweight), but only if you also have at least one weight-related health condition such as high blood pressure, type 2 diabetes, or high cholesterol.
These thresholds apply to adults. The FDA label specifically names hypertension, type 2 diabetes, and dyslipidemia (abnormal cholesterol or triglyceride levels) as qualifying comorbidities, though sleep apnea and other obesity-related conditions are commonly accepted in clinical practice. Your doctor calculates BMI from your current height and weight at the time of prescribing. For context, a BMI of 30 corresponds to roughly 210 pounds for someone who is 5’9″.
Qualifying for Heart Risk Reduction
In March 2024, the FDA approved Wegovy for a separate purpose: reducing the risk of heart attack, stroke, and cardiovascular death in adults who already have established cardiovascular disease and are either obese or overweight. This was the first drug approved specifically to lower serious heart risks in people with obesity or overweight.
The qualification here is narrower. You need both a documented history of cardiovascular disease (such as a prior heart attack, stroke, or peripheral artery disease) and a BMI of 27 or higher. This indication exists alongside the weight management approval, so some patients qualify under both.
Qualifying With Type 2 Diabetes
For Ozempic, the qualifying criteria are more straightforward: a confirmed diagnosis of type 2 diabetes in an adult. The FDA label does not specify a minimum A1c level or any particular lab threshold. Your doctor decides whether semaglutide is appropriate based on your overall diabetes management, what other medications you’ve tried, and your treatment goals.
Ozempic is not approved for type 1 diabetes, and the label specifically warns against use in patients with a history of pancreatitis. If you have type 2 diabetes along with established cardiovascular disease, you may also qualify under Ozempic’s secondary indication for reducing the risk of major cardiovascular events.
Adolescent Eligibility
Wegovy is approved for patients as young as 12 for weight management, making it one of the few GLP-1 medications available to adolescents. The qualifying standard for teens is a BMI above the 95th percentile for their age and sex, which is the clinical definition of obesity in pediatric patients. There is no lower “overweight with comorbidities” pathway for adolescents the way there is for adults. The American Academy of Pediatrics recommends pharmacotherapy alongside intensive behavioral and lifestyle interventions for this age group, and does not currently recommend weight loss medications for children under 12.
Liver Disease Qualification
A newer and less widely known indication: Wegovy is now also approved to treat a form of fatty liver disease called MASH (metabolic dysfunction-associated steatohepatitis, previously known as NASH) in adults. To qualify, you need a confirmed diagnosis of MASH without cirrhosis, with moderate to advanced scarring of the liver (stages F2 to F3 fibrosis). This is typically confirmed through imaging or liver biopsy. If you’ve been diagnosed with fatty liver disease, it’s worth asking your doctor whether your stage of liver scarring falls within this range.
Who Cannot Take Semaglutide
Certain medical conditions disqualify you entirely. The most important is a personal or family history of medullary thyroid cancer or a genetic condition called multiple endocrine neoplasia syndrome type 2 (MEN 2). This is a hard contraindication, meaning semaglutide should never be prescribed in these cases. If you have a known family history of thyroid cancer, your doctor will need to determine the specific type before considering semaglutide.
Semaglutide is also not recommended for people with severe gastroparesis, a condition where the stomach empties abnormally slowly. Since the drug itself slows gastric emptying as part of how it works, it can significantly worsen symptoms in people who already have this condition. Patients with type 1 diabetes are excluded from both Ozempic and Wegovy.
What Insurance Actually Requires
Meeting the FDA criteria gets you a prescription, but it doesn’t guarantee your insurance will cover it. Most insurers require prior authorization for semaglutide, and their standards are often stricter than the FDA’s. The specific requirements vary by plan, but a look at state Medicaid criteria illustrates the pattern.
Maryland’s Medicaid program, for example, only covers Wegovy for adults with documented cardiovascular disease and a BMI of 27 or higher, and explicitly excludes patients who have type 1 or type 2 diabetes. This is far more restrictive than the FDA label, which approves it for weight management regardless of heart disease history. The program also requires BMI documentation from within the last 90 days, meaning you’ll need a recent office visit with a recorded height and weight.
Private insurers often add their own hurdles. Common requirements include documentation that you’ve tried and failed to lose weight through diet and exercise alone, sometimes for a specific period like three to six months. Some plans require you to have tried other weight loss medications first. Others exclude weight management drugs from coverage entirely, though this is becoming less common as the cardiovascular benefits gain recognition.
If your insurance denies coverage, your doctor’s office can file an appeal with supporting medical documentation. Many manufacturers also offer savings programs or copay cards that reduce out-of-pocket costs, though these typically don’t apply to government insurance programs like Medicare or Medicaid. Without any coverage, the list price for semaglutide runs over $1,000 per month, making the insurance question a practical barrier for most people.
Steps to Get Started
The qualification process in practice involves a few concrete steps. Your doctor will record your current BMI, document any relevant health conditions (high blood pressure, diabetes, high cholesterol, cardiovascular disease, or liver disease), and review your medical history for contraindications. If you’re pursuing it for weight management, expect to discuss your history of diet and exercise efforts, since both the FDA label and most insurers require that semaglutide be used alongside a reduced-calorie diet and increased physical activity.
Your provider then submits a prior authorization request to your insurer, which typically takes a few days to a few weeks to process. If approved, the medication ships to a specialty pharmacy or is available at your local pharmacy depending on your plan. The standard protocol starts at a low dose and gradually increases over 16 to 20 weeks to reduce side effects like nausea, so full treatment effects take several months to kick in.